

**NYSTATIN- nystatin cream**  
**Padagis Israel Pharmaceuticals Ltd**

-----  
**NYSTATIN CREAM USP**

**For Dermatologic Use Only**


**Not For Ophthalmic Use**

**Rx Only**

**DESCRIPTION**

Nystatin is a polyene antifungal antibiotic obtained from *Streptomyces noursei*. The molecular formula is C<sub>47</sub>H<sub>75</sub>NO<sub>17</sub>, and the molecular weight is 926.13.

Structural formula:



Nystatin Cream USP is for dermatologic use.

Nystatin Cream USP for topical use, contains 100,000 USP nystatin units per gram.  
Inactive ingredients: emulsifying wax, glycerin, isopropyl myristate, lactic acid, purified water, sodium hydroxide, and sorbic acid.

**CLINICAL PHARMACOLOGY**

**Pharmacokinetics**

Nystatin Cream USP is not absorbed from intact skin or mucous membrane.

**Microbiology**

Nystatin is an antibiotic which is both fungistatic and fungicidal *in vitro* against a wide variety of yeasts and yeast-like fungi, including *Candida albicans*, *C. parapsilosis*, *C. tropicalis*, *C. guilliermondi*, *C. pseudotropicalis*, *C. krusei*, *Torulopsis glabrata*, *Trichophyton rubrum*, *T. mentagrophytes*.

Nystatin acts by binding to sterols in the cell membrane of susceptible species resulting in a change in membrane permeability and the subsequent leakage of intracellular components. On repeated subculturing with increasing levels of nystatin, *Candida albicans* does not develop resistance to nystatin. Generally, resistance to nystatin does not develop during therapy. However, other species of *Candida* (*C. tropicalis*, *C. guilliermondi*, *C. krusei*, and *C. stellatoidea*) become quite resistant on treatment with nystatin and simultaneously become cross resistant to amphotericin as well. This resistance is lost when the antibiotic is removed.

Nystatin exhibits no appreciable activity against bacteria, protozoa, or viruses.

## **INDICATIONS AND USAGE**

Nystatin Cream USP is indicated in the treatment of cutaneous or mucocutaneous mycotic infections caused by *Candida albicans* and other susceptible *Candida* species.

**Nystatin Cream USP is not indicated for systemic, oral, intravaginal or ophthalmic use.**

## **CONTRAINDICATIONS**

Nystatin Cream USP is contraindicated in patients with a history of hypersensitivity to any of its components.

## **PRECAUTIONS**

### **General -**

**Nystatin Cream USP should not be used for the treatment of systemic, oral, intravaginal or ophthalmic infections.**

If irritation or sensitization develops, treatment should be discontinued and appropriate measures taken as indicated. It is recommended that KOH smears, cultures, or other diagnostic methods be used to confirm the diagnosis of cutaneous or mucocutaneous candidiasis and to rule out infection caused by other pathogens.

### **Information for Patients -**

Patients using this medication should receive the following information and instructions:

1. The patient should be instructed to use this medication as directed (including the replacement of missed doses). This medication is not for any disorder other than that for which it is prescribed.
2. Even if symptomatic relief occurs within the first few days of treatment, the patient should be advised not to interrupt or discontinue therapy until the prescribed course of treatment is completed.
3. If symptoms of irritation develop, the patient should be advised to notify the physician promptly.

### **Laboratory Tests -**

If there is a lack of therapeutic response, KOH smears, cultures, or other diagnostic methods should be repeated.

### **Carcinogenesis, Mutagenesis, Impairment of Fertility -**

No long-term animal studies have been performed to evaluate the carcinogenic potential of Nystatin. No studies have been performed to determine the mutagenicity of Nystatin or its effects on male or female fertility

### **Pregnancy: Teratogenic Effects: Category C -**

Animal reproduction studies have not been conducted with any Nystatin topical preparation. It also is not known whether these preparations can cause fetal harm when used by a pregnant woman or can affect reproductive capacity. Nystatin topical preparations should be prescribed for a pregnant woman only if the potential benefit to the mother outweighs the potential risk to the fetus.

### **Nursing Mothers -**

It is not known whether Nystatin is excreted in human milk. Caution should be exercised when nystatin is prescribed for a nursing woman.

### **Pediatric Use -**

Safety and effectiveness have been established in the pediatric population from birth to 16 years (see **DOSAGE AND ADMINISTRATION**).

### **Geriatric Use -**

Clinical studies with nystatin cream did not include sufficient numbers of subjects aged 65 years and older to determine whether they respond differently than younger subjects. Other reported clinical experience has not identified differences in responses between elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.

## **ADVERSE REACTIONS**

The frequency of adverse events reported in patients using Nystatin Cream USP is less than 0.1%. The more common events that were reported include allergic reactions, burning, itching, rash, eczema, and pain on application (see **PRECAUTIONS-General**).

## **DOSAGE AND ADMINISTRATION**

Very moist lesions are best treated with nystatin topical dusting powder.

### **Adults and Pediatric Patients (Neonates and Older):**

Apply liberally to affected areas twice daily or as indicated until healing is complete.

## **HOW SUPPLIED**

Nystatin Cream USP (100,000 USP Nystatin Units per gram) is a yellow cream available

as follows:

15 g tube (NDC 45802-**059**-35)

30 g tube (NDC 45802-**059**-11)

**Storage**

Store at 20-25°C (68-77°F) [see USP Controlled Room Temperature].

Manufactured By Perrigo plc  
Bronx, NY 10457

Distributed By  
Padagis  
Allegan, MI 49010  
[www.padagis.com](http://www.padagis.com)

Rev 02-22

1P600 RC JX2

**Principal Display Panel**

Rx Only

NDC 45802-**059**-11

Nystatin Cream USP

(100,000 USP Nystatin Units)

NET WT 30 g



The following image is a placeholder representing the product identifier that is either affixed or imprinted on the drug package label during the packaging operation.

S/N [insert product's serial number]  
 Lot [insert product's lot number]  
 Exp [insert product's expiration date]

|  |                         |                           |               |
|--|-------------------------|---------------------------|---------------|
| <b>NYSTATIN</b>                        |                         |                           |               |
| nystatin cream                         |                         |                           |               |
| <b>Product Information</b>             |                         |                           |               |
| <b>Product Type</b>                    | HUMAN PRESCRIPTION DRUG | <b>Item Code (Source)</b> | NDC:45802-059 |
| <b>Route of Administration</b>         | TOPICAL                 |                           |               |
| <b>Active Ingredient/Active Moiety</b> |                         |                           |               |

| Ingredient Name  |  | Basis of Strength                                 | Strength              |                    |
|--|--|---|-----------------------|--------------------|
| Nystatin (UNII: BDF1O1C72E) (Nystatin - UNII:BDF1O1C72E) |  | Nystatin  | 100000 [USP'U] in 1 g |                    |
| <b>Inactive Ingredients</b>                              |  |   |                       |                    |
| Ingredient Name  |  |   | Strength              |                    |
| GLYCERIN (UNII: PDC6A3C00X)                              |  |   |                       |                    |
| ISOPROPYL MYRISTATE (UNII: 0RE8K4LNJS)                   |  |   |                       |                    |
| LACTIC ACID, UNSPECIFIED FORM (UNII: 33X04XA5AT)         |  |   |                       |                    |
| WATER (UNII: 059QF0K00R)                                 |  |   |                       |                    |
| SODIUM HYDROXIDE (UNII: 55X04QC32I)                      |  |   |                       |                    |
| SORBIC ACID (UNII: X045WJ989B)                           |  |   |                       |                    |
| <b>Packaging</b>   |  |   |                       |                    |
| #  | Item Code                                | Package Description                               | Marketing Start Date  | Marketing End Date |
| 1  | NDC:45802-059-35                         | 1 in 1 CARTON                                     | 01/25/2007            |                    |
| 1  |  | 15 g in 1 TUBE; Type 0: Not a Combination Product |                       |                    |
| 2  | NDC:45802-059-11                         | 1 in 1 CARTON                                     | 09/21/2006            |                    |
| 2  |  | 30 g in 1 TUBE; Type 0: Not a Combination Product |                       |                    |
| <b>Marketing Information</b>                             |  |   |                       |                    |
| Marketing Category                                       | Application Number or Monograph Citation | Marketing Start Date                              | Marketing End Date    |                    |
| ANDA   | ANDA062225                               | 09/21/2006  |                       |                    |

**Labeler** - Padagis Israel Pharmaceuticals Ltd (600093611)

Revised: 2/2022

Padagis Israel Pharmaceuticals Ltd